InMed Pharmaceuticals
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$1.97M
-0.3
-13.59
$4.83M
13
InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
emptyResult
InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Recently from Cashu
Please provide the content you'd like summarized, and I'll help create a title for you!
Certainly! Please provide the text or key points you would like summarized, and I'll create a 300-word summary focusing on InMed Pharmaceuticals or its industry.
Please provide the content you would like summarized about InMed Pharmaceuticals.
I apologize, but it seems I haven't received the content you'd like summarized. Please provide the text or key points regarding InMed Pharmaceuticals, and I would be happy to assist you with a concise…
It seems there was an error, and no content was provided for summarization. Please share the text you'd like summarized, and I'll help you create a suitable title!
Please provide the text you would like summarized, and I'd be happy to help!
Request for Content to Summarize Regarding InMed Pharmaceuticals
I'm sorry, but it seems that you haven't provided the content that you would like me to summarize. Please share the text or details that you want me to work with, and I'll be glad to help you create a…